A heart valve dedicated for aortic regurgitation: Review of technology and early clinical experience with the transfemoral Trilogy system.

AVD-aortic valve disease AVDP-aortic valve disease TVI-transcatheter valve implantation percutaneous intervention

Journal

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139

Informations de publication

Date de publication:
Oct 2023
Historique:
revised: 04 07 2023
received: 13 05 2023
accepted: 28 07 2023
pubmed: 10 8 2023
medline: 10 8 2023
entrez: 10 8 2023
Statut: ppublish

Résumé

Aortic regurgitation (AR) is associated with morbidity and premature mortality. Surgical aortic valve replacement is not an option for many patients due to an adverse surgical risk profile, whilst transcatheter aortic valve implantation with most available prostheses has demonstrated suboptimal implantation success and outcomes. The JenaValve Trilogy™ system provides an attractive solution for such patients as it utilizes clips that directly attach onto the native valve leaflets to anchor. Initially designed for transapical delivery, the current transfemoral delivery system is under investigation in the United States and approved for aortic stenosis and regurgitation in Europe. We present an expert review on the technical aspects of the Trilogy system, provide a guide for implantation, discuss the available evidence for the technology and provide illustrative case examples.

Identifiants

pubmed: 37560819
doi: 10.1002/ccd.30795
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

766-771

Informations de copyright

© 2023 The Authors. Catheterization and Cardiovascular Interventions published by Wiley Periodicals LLC.

Références

D'Arcy JL, Coffey S, Loudon MA, et al. Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people: The OxVALVE Population Cohort Study. Eur Heart J. 2016;37:3515-3522.
Koga-Ikuta A, Fukushima S, Kawamoto N, et al. Reverse remodelling after aortic valve replacement for chronic aortic regurgitation. Interact Cardiovasc Thorac Surg. 2021;33:10-18.
Bonow RO, Lakatos E, Maron BJ, Epstein SE. Serial long-term assessment of the natural history of asymptomatic patients with chronic aortic regurgitation and normal left ventricular systolic function. Circulation. 1991;84:1625-1635.
Tornos MP, Olona M, Permanyer-Miralda G, et al. Clinical outcome of severe asymptomatic chronic aortic regurgitation: a long-term prospective follow-up study. Am Heart J. 1995;130:333-339.
Thourani VH, Brennan JM, Edelman JJ, et al. Treatment patterns, disparities, and management strategies impact clinical outcomes in patients with symptomatic severe aortic regurgitation. Structural Heart. 2021;5:608-618.
Kolte D, Khera S, Vemulapalli S, et al. Outcomes following urgent/emergent transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2018;11:1175-1185.
Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease: developed by the task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;43:561-632.
Dong N, Jiang W, Yin P, Hu X, Wang Y. Predictors of long-term outcome of isolated surgical aortic valve replacement in aortic regurgitation with reduced left ventricular ejection fraction and extreme left ventricular dilatation. Am J Cardiol. 2020;125:1385-1390.
Dujardin KS, Enriquez-Sarano M, Schaff HV, Bailey KR, Seward JB, Tajik AJ. Mortality and morbidity of aortic regurgitation in clinical practice. Circulation. 1999;99:1851-1857.
Malahfji M, Crudo V, Kaolawanich Y, et al. Influence of cardiac remodeling on clinical outcomes in patients with aortic regurgitation. JACC. 2023;81:1885-1898.
MacDonald ZD, Yousef A, Simard T, et al. Transcatheter aortic valve implantation (TAVI) in native aortic valve regurgitation: a systematic review. Can J Cardiol. 2016;32:S100.
Takagi H, Hari Y, Kawai N, Ando T. Meta-analysis and meta-regression of transcatheter aortic valve implantation for pure native aortic regurgitation. Heart, Lung Circ. 2020;29:729-741.
Yoon S-H, Schmidt T, Bleiziffer S, et al. Transcatheter aortic valve replacement in pure native aortic valve regurgitation. JACC. 2017;70:2752-2763.
Tamm A. JenaValve Trilogy Heart Valve System. Transcatheter Ther. Boston USA. 2022.
JenaValve ALIGN-AR Pivotal Trial. ClinicaltrialsGov; 2020.
Ranard LS, Kaple R, Khalique OK, et al. First transfemoral implantation of a novel transcatheter valve in an LVAD patient with aortic insufficiency. JACC: Case Rep. 2021;3:1806-1810.
Hiroaki Y, Alexander TR, Martin G, Thomas M, Hendrik T, Stephan von BR. Treatment of severe aortic valve regurgitation with the Trilogy TAVI system. EuroIntervention. 2023;18:1444-1445.

Auteurs

Andreas Baumbach (A)

Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London, London, UK.
Barts Heart Centre, St Bartholomew's Hospital, London, UK.

Kush P Patel (KP)

Barts Heart Centre, St Bartholomew's Hospital, London, UK.

Simon Kennon (S)

Barts Heart Centre, St Bartholomew's Hospital, London, UK.

Mick Ozkor (M)

Barts Heart Centre, St Bartholomew's Hospital, London, UK.

Anthony Mathur (A)

Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London, London, UK.
Barts Heart Centre, St Bartholomew's Hospital, London, UK.

Frank de la Huerta (F)

JenaValve Technology, Inc., Irvine, California, USA.

Alexander R Tamm (AR)

Department of Cardiology, Cardiology I, University Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Germany.

Classifications MeSH